Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|516571-25MG||Glass bottle||25 mg||
|Overview||A cell-permeable thiazolidinedione that acts as a PPARγ-selective agonist (Ki = 160 nM) and blocks Cdk-5-mediated Ser273 phosphorylation by stabilizing PPARγ β-sheet structure, exhibiting no detectable activity towards PPARα, PPARδ, or RXRα. Although a weaker PPAPγ agonist than Thiazolidinediones (TZDs) family rosiglitazone (Cat. No. 557366; Max. fold of transactivation induction = 8.57 and 24.8 with 10 µM respective compound in U-937 reporter assays), GQ-16 can be safely administered at a higher dosage (20 mg/kg/day; oral gavage) in mice to achieve similar in vivo efficacy as rosiglitazone (4 mg/kg/day; o.g.) without adverse side effects commonly seen with TZDs.|
|References||Amato, A.A., et al. 2012. J. Biol. Chem. 287, 28169.|
|Form||Pale yellow solid|
|Structure formula Image|
|Purity||≥99% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Amato, A.A., et al. 2012. J. Biol. Chem. 287, 28169.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.